

April 16th. 1980.

England

Dear Mr. Yoshioka,

Re: Japanese Patent Appln. No. 26463/78
Your ref: CH:RY, File: F-134-2)

Thank you for your letter of April 10th. 1980. There seems to be some misunderstanding by the Japanese Patent Office as to the nature of the patent for which I am applying.

All the substances mentioned in the patents, namely Clotrimazole (Canestan), Metronidazole (Flagyl), Tinidazole (Fasigyn), Ornidazole (Tiberal), and Nimorazole (Naxogin), are all drugs which are already available commercially in Japan. They have not been made by me but by well-known and world wide Pharmaceutical companies, who obviously have already submitted to the Japanese Patent Office all the toxicity data that they require in order for them to become commercially available in Japan. It is, therefore, completely unnecessary for me to submit such data, which they already have,.

The patent application which I wish to apply for is the use of these substances in the treatment of active rheumatoid arthritis. This disease has never been treated in this manner until my discovery of the cause of the disease and the fact that these drugs kill the causative organism of this disease in the laboratory and in man.

Please indicate to the Patent Office the exact nature of my patent application because they do not seem to understand what I am applying for. I again stress that all these drugs would not be available commercially in Japan, as they already are, unless all the toxicity data had already been received by the Patent Office from the makers of the various drugs. I am not applying for the patent of new drugs but for the patent of the new use of these drugs.

Yours sincerely,